Sun Pharma Advanced Research Company Ltd

SPARC Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharma Advanced Research Company Ltd

₹ 221 -6.04%
27 May - close price
sparc.life BSE: 532872 NSE: SPARC
About

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

Key Points

Leadership[1]
First listed pharma R&D company out of India where founders still own 70% and continue to invest.

Website BSE NSE
  • Market Cap ₹ 7,183 Cr.
  • Current Price ₹ 221
  • High / Low ₹ 249 / 108
  • Stock P/E 4.59
  • Book Value ₹ 41.1
  • Dividend Yield 0.00 %
  • ROCE 165 %
  • ROE 281 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has delivered good profit growth of 65.3% CAGR over last 5 years

Cons

  • Stock is trading at 5.39 times its book value
  • Working capital days have increased from -770 days to 214 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty Microcap 250 Nifty Total Market BSE 1000 Nifty Smallcap 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
48 24 21 14 17 17 13 15 27 10 8 8 1,853
137 126 113 116 124 112 117 89 81 62 74 65 80
Operating Profit -90 -102 -91 -103 -108 -95 -104 -74 -54 -52 -66 -57 1,773
OPM % -188% -427% -432% -740% -649% -566% -808% -499% -198% -543% -838% -673% 96%
11 10 8 6 4 2 0 0 0 9 0 -12 2
Interest 0 0 0 0 1 1 1 3 5 6 8 9 12
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 2
Profit before tax -82 -95 -86 -100 -107 -97 -108 -80 -61 -52 -76 -81 1,761
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-82 -95 -86 -100 -107 -97 -108 -80 -61 -52 -76 -81 1,761
EPS in Rs -2.53 -2.94 -2.66 -3.07 -3.29 -2.98 -3.32 -2.46 -1.88 -1.60 -2.34 -2.48 54.26
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
156 161 181 78 183 77 253 137 239 76 72 1,879
191 224 304 321 334 387 388 324 453 479 399 281
Operating Profit -35 -63 -123 -243 -151 -310 -135 -187 -214 -404 -327 1,598
OPM % -23% -39% -68% -310% -83% -404% -53% -136% -90% -534% -456% 85%
3 3 14 54 14 10 5 7 11 29 2 -2
Interest 0 2 2 0 0 3 11 13 8 2 9 34
Depreciation 7 8 8 8 8 9 11 10 12 12 11 10
Profit before tax -40 -70 -119 -197 -145 -312 -151 -203 -223 -388 -345 1,552
Tax % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
-40 -70 -119 -197 -145 -312 -151 -203 -223 -388 -345 1,552
EPS in Rs -1.60 -2.83 -4.82 -7.85 -5.55 -11.92 -5.77 -7.48 -6.86 -11.96 -10.64 47.83
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 28%
5 Years: 49%
3 Years: 99%
TTM: 2518%
Compounded Profit Growth
10 Years: 38%
5 Years: 65%
3 Years: 108%
TTM: 553%
Stock Price CAGR
10 Years: -3%
5 Years: 0%
3 Years: 7%
1 Year: 30%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 281%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 24 24 25 25 26 26 26 27 32 32 32 32
Reserves 76 8 133 160 270 -45 -194 4 480 92 -253 1,301
4 56 3 2 2 67 236 79 16 56 265 559
39 75 111 122 101 224 162 170 302 305 284 275
Total Liabilities 143 163 273 309 398 273 230 280 830 486 329 2,168
67 70 69 52 58 104 91 92 106 103 95 157
CWIP 0 1 1 3 24 32 5 26 27 44 54 0
Investments 0 0 10 108 211 8 6 12 291 2 0 0
76 92 192 146 106 128 127 150 406 338 179 2,011
Total Assets 143 163 273 309 398 273 230 280 830 486 329 2,168

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-41 -44 -128 -183 -172 -211 -152 -208 -69 -429 -362 -239
53 -13 -7 -105 -102 155 2 -29 -548 391 158 -24
-1 51 194 224 274 55 159 229 617 43 201 262
Net Cash Flow 11 -7 60 -63 0 0 9 -8 -1 4 -4 -1
Free Cash Flow -49 -56 -136 -200 -184 -264 -153 -233 -84 -455 -372 -262
CFO/OP 110% 48% 88% 71% 111% 65% 111% 114% 35% 105% 114% -17%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 47 21 78 82 20 76 25 74 50 75 82 2
Inventory Days 0 0 0 0 0 0 0 0
Days Payable
Cash Conversion Cycle 47 21 78 82 20 76 25 74 50 75 82 2
Working Capital Days 20 -161 -60 -232 -98 -842 -268 -301 -193 -746 -1,778 214
ROCE % -32% -71% -94% -143% -62% -183% -242% -218% -67% -109% -298% 165%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Total Employee Count
Number

Log in to view insights

Please log in to see hidden values.

Login
Scientist Strength
Number
Number of R&D Centers
Number
Products in Active Clinical Pipeline
Number
Learning and Development Hours
Hours
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

13 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.68% 65.67% 65.67% 65.67% 65.67%
3.64% 3.67% 3.30% 3.24% 2.64% 2.15% 2.23% 1.45% 1.47% 1.76% 2.04% 2.04%
0.63% 0.65% 0.67% 0.67% 0.17% 0.21% 0.64% 1.13% 0.97% 1.05% 0.78% 0.88%
30.06% 29.99% 30.36% 30.41% 31.51% 31.96% 31.47% 31.76% 31.88% 31.52% 31.51% 31.41%
No. of Shareholders 1,00,8071,01,4331,03,9901,02,7431,25,1841,28,2051,31,0341,42,8641,40,7241,36,9971,44,8101,40,625

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls